Repligen Corporation (RGEN)
RGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1986 |
| SEC CIK | 0000730272 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $738.3M |
| Net income | $48.9M |
| Operating income | $55.2M |
| Net margin | 6.6% |
| Operating margin | 7.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $566.0M |
| Total assets | $2.9B |
| P/E (computed) | 175.5× |
| P/S (computed) | 11.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-04 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-07-29 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.6% |
| 1 month | +2.0% |
| 3 months | +20.0% |
| Year to date | +8.8% |
| 1 year | +19.9% |
| From 52-week high | -8.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
| KRYS | Krystal Biotech Inc. | $321.16 | -3.29% | $9.5B |
| TWST | Twist Bioscience Corporation | $151.33 | -0.35% | $10.0B |
| IBRX | ImmunityBio Inc. | $9.80 | -3.16% | $10.4B |
| PCVX | Vaxcyte Inc. | $66.80 | -5.45% | $10.5B |
| IOVA | Iovance Biotherapeutics Inc. | $14.50 | -0.41% | $6.6B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier